Potential of Natural-Based Anticancer Compounds for P-Glycoprotein Inhibition
2018
Preuzimanje 🢃
Tip dokumenta:
Članak u časopisu (Recenzirana verzija)
,
© 2018 Bentham Science Publishers
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
Medicinal value of natural products comes from symbiotic and competitive evolution in Earth's complex biosphere. Billions of years of co-evolutionary interactions among millions of species have produced a large repertoire of defense molecules effective in fighting bacteria, viral, and fungal pathogens. Each species contains millions of different and useful molecules and new research technologies enabled the screening of molecules and complex mixtures from diverse biological sources. Traditional use of plants and other species led to the discovery of many bioactive compounds with various properties. In the last four decades, a large number of them were evaluated for their potential to treat cancer. Penetration of drugs into the cancer cell is necessary for their lethal pharmacological effect through interaction with intracellular target molecules. Increased activity of membrane efflux pumps reduces the intracellular drug accumulation, thereby preventing drug-target interactions. The discovery of the efflux transporter P-glycoprotein (P-gp) in multidrug resistant (MDR) cancer cells prompted the efforts in overcoming drug resistance by P-gp inhibition. The search for nontoxic anticancer agents from natural sources able to overcome MDR has been imperative in the field of drug design and discovery. Herein, we review various natural compounds from diverse sources emphasizing their potential to inhibit P-gp activity and/or expression.
Napomena:
The published manuscript is available at EurekaSelect via https://www.eurekaselect.com/168955/article.
Related to: https://radar.ibiss.bg.ac.rs/handle/123456789/3322
Ključne reči:
ATP-Binding Cassette transporters; Multidrug resistance; P-glycoprotein; Anticancer compounds; Traditional medicine; Natural productsIzvor:
Current Pharmaceutical Design, 2018, 24, 36, 4334-Finansiranje / projekti:
- Identifikacija molekularnih markera za predikciju progresije tumora, odgovora na terapiju i ishoda bolesti (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41031)
- COST Actions CM1106 (Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells)
- COST Action CM1407 (Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery)
DOI: 10.2174/1381612825666190112164211
ISSN: 1381-6128
PubMed: 30648503